CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Annexon outlines Q4 BLA filing for tanruprubart while adding month 24 dual primary endpoint to ARCHER II

BLA FilingtanruprubartPositive
AI Analysis

Summary

Annexon plans to submit a Biologics License Application (BLA) for tanruprubart in Q4 2026 and has added a month 24 dual primary endpoint to the ARCHER II trial.

Clinical Trial Data

Importance:7/10
Sentiment:
0.50
BLAtanruprubartARCHER IIdual primary endpoint

Read the original article

Published by Seeking Alpha Healthcare on August 12, 2026 6:08 PM

Read Original